| |
Antibiotic
Susceptibility E TEST : Keratitis Conjunctivitis Endophthalmitis
Susceptibility*
of Bacterial Isolates from Keratitis to Common Antibiotics
(January 1, 2020 through December 31, 2021)
Staphylococcus aureus (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| VANCOMYCIN |
64 |
0.38 |
0.75 |
.75 |
1.00 |
1.50 |
< 2 |
> 16 |
| GENTAMICIN |
64 |
0.064 |
0.125 |
0.19 |
0.19 |
4.00 |
< 4 |
> 16 |
| MOXIFLOXACIN |
59 |
0.023 |
0.047 |
0.094 |
.25 |
12.00 |
< 0.5 |
> 2 |
| CEFOXITIN |
62 |
3.0 |
4.0 |
4.0 |
24.0 |
128.0 |
< 4 |
> 8 |
| CEFAZOLIN |
62 |
0.38 |
0.75 |
1.00 |
2.25 |
96.00 |
NS |
NS |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Pseudomonas aeruginosa (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| TOBRAMYCIN |
38 |
0.38 |
1.0 |
1.50 |
2.00 |
6.00 |
< 4 |
> 16 |
| CEFTAZIDIME |
38 |
0.75 |
1.375 |
1.50 |
2.0 |
4.00 |
< 8 |
> 32 |
| CIPROFLOXACIN |
38 |
0.017 |
0.064 |
0.094 |
0.125 |
1.00 |
< 0.5 |
> 2 |
| POLYMYXIN B |
38 |
0.75 |
1.50 |
1.75 |
2.25 |
6.0 |
< 2 |
> 8 |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested.
|
Coagulase Negative Staphylococcus (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| VANCOMYCIN |
21 |
0.25 |
1.00 |
1.50 |
1.50 |
3.00 |
< 4 |
> 32 |
| GENTAMICIN |
21 |
0.03 |
0.09 |
0.25 |
19.0 |
192.00 |
< 4 |
> 16 |
| MOXIFLOXACIN |
21 |
0.03 |
0.47 |
2.00 |
36.00 |
64.00 |
< 0.5 |
> 2 |
| CEFAZOLIN |
21 |
0.25 |
0.50 |
1.5 |
3.00 |
12.00 |
NS |
NS |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Streptococcus viridans (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| VANCOMYCIN |
14 |
0.25 |
0.47 |
0.50 |
0.81 |
2.00 |
<1 |
- |
| GENTAMICIN |
8 |
0.38 |
1.06 |
2.0 |
12.75 |
32.00 |
< 4 |
> 16 |
| MOXIFLOXACIN |
14 |
0.064 |
0.094 |
0.125 |
0.19 |
0.38 |
<1 |
> 4 |
| CEFAZOLIN |
9 |
0.02 |
0.16 |
0.25 |
2.25 |
16 |
NS |
NS |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Other Gram Positive bacteria (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| VANCOMYCIN |
12 |
0.38 |
0.38 |
0.5 |
1.0 |
1.5 |
<1 |
- |
| GENTAMICIN |
6 |
0.0 |
0.8 |
2.5 |
60.0 |
96.0 |
< 4 |
> 16 |
| MOXIFLOXACIN |
10 |
0.094 |
0.174 |
.315 |
0.47 |
4.0 |
< 1 |
> 4 |
| CEFAZOLIN |
11 |
0.0 |
0.1 |
0.3 |
24.0 |
128 |
NS |
NS |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Other Gram Negative bacteria (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| TOBRAMYCIN |
15 |
0.25 |
0.38 |
1.0 |
1.5 |
3.00 |
< 4 |
> 16 |
| CEFTAZIDIME |
14 |
0.064 |
0.125 |
0.19 |
1.0 |
3.0 |
< 8 |
> 32 |
| CIPROFLOXACIN |
14 |
0.012 |
0.021 |
0.032 |
0.33 |
4.00 |
< 1 |
> 4 |
| POLYMYXIN B |
13 |
0.00 |
0.63 |
1.00 |
4.75 |
32.00 |
< 2 |
> 8 |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested.
|
Moraxella (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
|
|
| TOBRAMYCIN |
13 |
0.0160 |
0.2200 |
0.5000 |
0.6250 |
1.00 |
|
|
| CEFTAZIDIME |
12 |
0.0160 |
0.0470 |
0.0940 |
0.1250 |
0.3800 |
|
|
| CIPROFLOXACIN |
12 |
0.0080 |
0.0130 |
0.0195 |
0.0297 |
0.9600 |
|
|
| POLYMYXIN B |
12 |
0.1900 |
0.2500 |
0.3150 |
0.3800 |
0.7500 |
|
|
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested.
|
Susceptibility*
of Bacterial Isolates from Conjunctivitis to Common Antibiotics
(January 1, 2020 through December 31, 2021)
Staphylococcus aureus (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| MOXIFLOXACIN |
45 |
0.03 |
0.05 |
0.09 |
2.0 |
64.00 |
< 0.5 |
> 2 |
| CEFOXITIN |
48 |
0.8 |
4.0 |
4.0 |
15.0 |
512.0 |
< 4 |
> 8 |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Other Gram Positive bacteria (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| MOXIFLOXACIN |
10 |
0.064 |
0.19 |
0.25 |
0.25 |
0.50 |
< 1 |
> 4 |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested.
|
Gram Negative bacteria (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| TOBRAMYCIN |
23 |
0.5 |
0.75 |
1.00 |
1.50 |
32 |
< 4 |
> 16 |
| CIPROFLOXACIN |
23 |
0.008 |
0.016 |
0.047 |
0.38 |
0.63 |
< 1 |
> 4 |
| POLYMYXIN B |
22 |
0.00 |
0.15 |
1.0 |
2.0 |
64 |
< 2 |
> 8 |
| MOXIFLOXACIN |
4 |
0.047 |
0.11 |
0.19 |
0.69 |
6.0 |
NS |
NS |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested. NS= No Standards
|
Susceptibility*
of Bacterial Isolates from Endophthalmitis to Common Antibiotics
(January 1, 2020 through December 31, 2021)
Gram Positive bacteria (MIC= ug/ml) |
| ANTIBIOTIC |
# |
MIN |
Q1 |
MEDIAN |
Q3 |
MAXIMUM |
MIC SUSCEPTIBLE |
MIC RESISTANT |
| VANCOMYCIN |
44 |
0.25 |
0.75 |
1.0 |
1.5 |
2.00 |
< 4 |
> 32 |
| * Antibiotic susceptibilities are based on serum concentrations and NOT concentrations achieved in the corneal tissue. |
(#) = Number of isolates tested.
|
|
|
|
|
